Revlimid 10 MG capsule 28S
Ended Awarded Last action
- Contract number
- SPE2DR26FM3NF
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,643
Award facts
- Contract value 100% obligated
- $33,642.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at approximately $33.6K by the Defense Logistics Agency (DLA) on January 29, 2026, for the supply of Revlimid 10 mg capsules (quantity: 28-count packages). This firm fixed-price, non-set-aside contract is scheduled for completion by February 20, 2026, with performance at the awardee's facility in Conshohocken, Pennsylvania. The delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at up to $1 billion through December 2026, which serves as the primary vehicle for pharmaceutical and medical supply procurement supporting military healthcare systems globally.
AmerisourceBergen's substantial $1 billion IDC with DLA encompasses a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The company's federal contract portfolio demonstrates consistent capability in fulfilling competitive procurement requirements for military treatment facilities, the Defense Health Agency, the U.S. Coast Guard, and other government healthcare systems. The current delivery order for Revlimid, an oncology medication used in the treatment of multiple myeloma and myelodysplastic syndromes, exemplifies the company's role as a critical pharmaceutical vendor supporting federal medical supply needs.
Quick answers
Who was awarded contract SPE2DR26FM3NF?
SPE2DR26FM3NF was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FM3NF worth?
The government has obligated $33,643 on SPE2DR26FM3NF.
Is contract SPE2DR26FM3NF an order under another contract?
Yes. SPE2DR26FM3NF is a delivery order under SPE2DR25D3501, an indefinite delivery contract.
Was contract SPE2DR26FM3NF competed?
The extent of competition for SPE2DR26FM3NF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award